Nazzani S, et al. - In patients treated with nephroureterectomy (NU) for non-metastatic locally advanced upper tract urothelial carcinoma, authors evaluated the potential survival benefit of perioperative chemotherapy (CHT). For patients with locally advanced non-metastatic upper tract urothelial carcinoma, lower overall mortality (OM) after CHT was suggested, it is specific in patients with T3–T4, N1–N3, M0 disease. A contemporary North American report was provided in the findings. Independent predictor status for lower OM was achieved by CHT in multivariable Cox regression models (MCRMs) testing for OM in patients with lymph node invasion (LNI). They confirmed following the inverse probability after treatment weighting (IPTW) adjustment and in landmark analyses.